ChemotherapyPhase 3 trialInvestigational
Decitabine
How it works
Interferes with DNA synthesis, preventing cancer cell growth and division.
Cancer types
Leukemia— MDS
Efficacy
In clinical trials, around 50% of patients with MDS achieved a complete or partial response.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Tested for Older AML Patients | Leukemia | phase-3 | Median overall survival was 8.2 months with ATRA versus 5.1 months without ATRA. | Source → |
| Testing a New Treatment for High-Risk Acute Myeloid Leukemia in Children | Leukemia | phase-1 | — | Source → |
| Study of Decitabine, Venetoclax, and Ponatinib for Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| Testing Oral Decitabine and Cedazuridine in Cancer Patients with Kidney Issues | Leukemia | phase-1 | — | Source → |
| Testing Oral Decitabine and Cedazuridine in Cancer Patients with Liver Problems | Leukemia | phase-1 | — | Source → |
| Genetically Modified T Cells and Decitabine in Treating Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing New Combination Therapy for Blood Cancers | Leukemia | phase-1 | — | Source → |
| Testing Combination Therapy for Advanced Leukemia | Leukemia | phase-1 | — | Source → |
| Cancer Gene Methylation Linked to Poor Prognosis in Leukemia | Leukemia | lab-study | Hypermethylation of the miR-34c CpG island correlated with shorter overall survival. | Source → |
| Researchers Identify Gene Mutation Linked to Resistance to Cancer Treatment | Leukemia | lab-study | — | Source → |
| Understanding How Decitabine Affects Cancer Cells | Leukemia | lab-study | — | Source → |
| Woman develops rare skin condition after leukemia treatment | Leukemia | observational | — | Source → |
| Elderly AML Patient Achieves Long Remission with Decitabine and Retinoic Acid | Leukemia | phase-2 | The patient attained a complete hematologic and cytogenetic remission with 3.7 years survival after 30 treatment cycles. | Source → |
| Combining Cancer Drugs May Improve Treatment for Breast and Ovarian Cancers | Ovarian Cancer | lab-study | Cell proliferation was inhibited by 48-70%, and Annexin V positivity was 42-59% in all cell lines exposed to the three-drug combinations. | Source → |
| Targeting a Key Enzyme in Leukemia Cells | Leukemia | phase-2 | — | Source → |
| Understanding DNA Methyltransferase Inhibitors in Cancer Treatment | Leukemia | review | — | Source → |
| Age and sex may affect treatment outcomes in older leukemia patients | Leukemia | phase-2 | Age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). | Source → |
| Decitabine and EIAG Regimen for Relapsed/Refractory AML and MDS | Leukemia | phase-2 | The overall response rate was 86.4% in the D-EIAG group. | Source → |
| Stem Cell Transplantation with Decitabine May Help Some Patients with Blood Disorders | Leukemia | observational | The 5-year overall survival rate was 72.7%. | Source → |
| Decitabine May Help Prevent Leukemia Relapse After Transplant | Leukemia | observational | The 3-year cumulative incidence of relapse rate in the dec group was lower than that in the ctrl group (19.6 vs. 36.1%). | Source → |
| Cancer Cells May Transfer Resistance to Treatment through Tiny Particles | Leukemia | lab-study | — | Source → |
| Researchers Investigate Epigenetic Regulation in Lung Cancer Cells | Lung Cancer | lab-study | The NY-ESO-1 protein was induced with a significant increase (**p < 0.0097). | Source → |
| New Treatments for Older Adults with Acute Myeloid Leukemia | Leukemia | review | — | Source → |
| Combining Decitabine and All-Trans Retinoic Acid May Improve Leukemia Treatment | Leukemia | lab-study | When combined, decitabine and all-trans retinoic acid resulted in an improved response rate and longer overall survival in a randomized phase II trial. | Source → |
| Venetoclax and Azacitidine or Decitabine Combination Therapy Risks in Acute Myeloid Leukemia | Leukemia | observational | — | Source → |
| Combining Epigenetic and Chemotherapy Treatments for Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Combining Decitabine and Rapamycin in Leukemia Treatment | Leukemia | phase-2 | The composite complete remission rate was 33%. | Source → |
| New Insights into DNA Hypomethylating Therapy for Leukemia | Leukemia | review | — | Source → |
| New Treatment Shows Promise for Relapsed Leukemia Patients | Leukemia | phase-3 | DEC10-VEN conferred significantly higher responses compared with IC including higher overall response rate (60% vs 36%) | Source → |
| Decitabine Treatment in Acute Myeloid Leukemia Patients | Leukemia | observational | The overall response rate was 30% and the median overall survival was 4.7 months. | Source → |
| Decitabine May Help Treat Myeloid Leukemia by Targeting TIGAR | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.